ML
$129.10
-0.10
(-0.08%)
As of Oct 22, 2026, 8:40 PM EDT
Price history
Mesa Laboratories Inc (MLAB) is trading down at $129.10 (-0.08%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Mesa Laboratories Inc revenue & net income history (FY2017–FY2026)
RevenueNet incomeNet margin (right axis, %)
| FY2017Mar 2017 | FY2018Mar 2018 | FY2019Mar 2019 | FY2020Mar 2020 | FY2021Mar 2021 | FY2022Mar 2022 | FY2023Mar 2023 | FY2024Mar 2024 | FY2025Mar 2025 | FY2026Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $93.7M | $96.2M | $103.1M | $117.7M | $133.9M | $184.3M | $219.1M | $216.2M | $241.0M | $249.1M |
| Growth (year over year) | +10.6% | +2.7% | +7.2% | +14.1% | +13.8% | +37.6% | +18.8% | −1.3% | +11.5% | +3.4% |
| Gross profit | $53.2M | $54.6M | $60.9M | $65.4M | $87.0M | $109.1M | $133.7M | $133.3M | $150.9M | $158.3M |
| Gross margin | 56.8% | 56.8% | 59.1% | 55.5% | 65.0% | 59.2% | 61.0% | 61.6% | 62.6% | 63.5% |
| Operating income | $16.3M | $2.18M | $9.78M | $7.92M | $12.4M | $4.70M | $3.32M | −$272.1M | $16.3M | $18.5M |
| Operating margin | 17.4% | 2.3% | 9.5% | 6.7% | 9.2% | 2.6% | 1.5% | −125.9% | 6.8% | 7.4% |
| Net income | $11.2M | −$2.96M | $7.48M | $1.78M | $3.27M | $1.87M | $930.0K | −$254.2M | −$1.97M | $6.71M |
| Net margin | 11.9% | −3.1% | 7.3% | 1.5% | 2.4% | 1.0% | 0.4% | −117.6% | −0.8% | 2.7% |
| EPS (diluted) | $2.91 | −$0.79 | $1.86 | $0.41 | $0.64 | $0.35 | $0.17 | −$47.20 | −$0.36 | $1.21 |
| Balance sheet | ||||||||||
| Cash and equivalents | $5.82M | $5.47M | $10.2M | $81.4M | $263.9M | $49.3M | $32.9M | $28.2M | $27.3M | $26.9M |
| Total assets | $171.7M | $164.1M | $156.8M | $409.1M | $601.5M | $707.4M | $661.8M | $446.8M | $433.3M | $427.7M |
| Total liabilities | $73.9M | $64.7M | $45.5M | $189.1M | $195.2M | $313.6M | $268.4M | $301.4M | $273.5M | $241.5M |
| Long-term debt | $53.7M | $44.6M | $20.6M | — | — | — | — | — | $71.3M | $67.5M |
| Shareholders' equity | $97.8M | $99.4M | $111.3M | $220.0M | $406.2M | $393.8M | $393.5M | $145.4M | $159.8M | $186.2M |
| Cash flow | ||||||||||
| Operating cash flow | $17.3M | $25.7M | $30.6M | $27.0M | $37.1M | $39.2M | $28.0M | $44.1M | $46.8M | $42.8M |
| Capital expenditure | — | $2.80M | $1.26M | $1.50M | $1.99M | $4.43M | $4.54M | $2.57M | $4.25M | $3.25M |
| Free cash flow | — | $22.9M | $29.3M | $25.5M | $35.1M | $34.8M | $23.4M | $41.6M | $42.6M | $39.6M |
| Dividends paid | $2.35M | $2.41M | $2.46M | $2.72M | $3.17M | $3.34M | $3.41M | $3.45M | $3.47M | $3.52M |
RevenueNet incomeNet margin (right axis, %)
| Q2 FY25Sep 2024 | Q3 FY25Dec 2024 | Q4 FY25†Mar 2025 | Q1 FY26Jun 2025 | Q2 FY26Sep 2025 | Q3 FY26Dec 2025 | Q4 FY26†Mar 2026 | Q1 FY27Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $57.8M | $62.8M | $62.1M | $59.5M | $60.7M | $65.1M | $63.7M | $60.1M |
| Growth (year over year) | +8.8% | +17.5% | +5.5% | +2.4% | +5.0% | +3.6% | +2.6% | +1.0% |
| Gross profit | $35.5M | $39.8M | $38.4M | $36.9M | $37.3M | $41.8M | $42.2M | $39.0M |
| Gross margin | 61.3% | 63.3% | 61.8% | 62.0% | 61.5% | 64.2% | 66.2% | 64.9% |
| Operating income | $3.51M | $5.78M | $1.47M | $3.06M | $4.72M | $7.97M | $2.75M | $7.03M |
| Operating margin | 6.1% | 9.2% | 2.4% | 5.1% | 7.8% | 12.2% | 4.3% | 11.7% |
| Net income | $3.43M | −$1.68M | −$7.11M | $4.74M | $2.48M | $3.63M | −$4.14M | $2.83M |
| Net margin | 5.9% | −2.7% | −11.4% | 8.0% | 4.1% | 5.6% | −6.5% | 4.7% |
| EPS (diluted) | $0.63 | −$0.31 | −$1.30 | $0.85 | $0.45 | $0.65 | −$0.74 | $0.49 |
| Balance sheet | ||||||||
| Cash and equivalents | $24.3M | $27.3M | $27.3M | $21.3M | $20.4M | $29.0M | $26.9M | $30.7M |
| Total assets | $454.1M | $433.3M | $433.3M | $435.7M | $430.4M | $434.8M | $427.7M | $419.2M |
| Total liabilities | $292.6M | $273.5M | $273.5M | $263.2M | $251.9M | $248.2M | $241.5M | $230.5M |
| Long-term debt | $73.1M | $72.2M | $71.3M | $70.3M | $69.4M | $68.4M | $67.5M | $66.1M |
| Shareholders' equity | $161.5M | $155.2M | $159.8M | $172.5M | $178.5M | $186.7M | $186.2M | $188.8M |
| Cash flow | ||||||||
| Operating cash flow | $5.27M | $18.1M | $12.7M | $1.89M | $8.22M | $18.8M | $14.0M | $14.7M |
| Capital expenditure | $1.79M | $813.0K | $757.0K | $1.01M | $1.09M | $732.0K | $417.0K | $559.0K |
| Free cash flow | $3.48M | $17.3M | $11.9M | $884.0K | $7.13M | $18.0M | $13.5M | $14.2M |
| Dividends paid | $866.0K | $869.0K | $870.0K | $873.0K | $882.0K | $884.0K | $884.0K | $884.0K |
From Mesa Laboratories Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in March. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Mesa Laboratories Inc
- Headquarters
- Lakewood, Colorado From SEC filings, Oct 2026
Recent News (2)
-
Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth The Restructuring Program focuses Clinical Genomics on profitability and adds resources in Sterilization and Disinfection Control, Calibration Solutions and Asia The Restructuring Program focuses Cli…
-
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International